Evercore ISI initiated coverage of OnKure Therapeutics (OKUR) with an Outperform rating. OnKure “has a lot to prove” with their upcoming Phase 1 results, but if they can maintain a cleaner safety profile than competitors and win a partnership with an early-line combination, the firm expects “significant upside,” Evercore tells investors. However, if the company falters on either front, the firm argues that “even an active drug will struggle to find relevance,” adding that safety in combination is the key to unlocking upside and where OnKure “looks most differentiated.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKUR:
- OnKure Therapeutics price target lowered to $34 from $40 at H.C. Wainwright
- Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025
- Oppenheimer biotech analyst holds an analyst/industry conference call
- Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects
- Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue